New option listings for January 22nd include Aardvark Therapeutics Inc (AARD), Anteris Technologies Global Corp (AVR), Climb Bio Inc (CLYM), REX Drone ETF (DRNZ), Grace Therapeutics, Inc (GRCE), Infinity Natural Resources Inc (INR), Jyong Biotech Ltd (MENS), NovaBay (NBY), NGEN Inc (NGEN), and PolyPid (PYPD). Option delistings effective January 22nd include StoneCastle (BANX) and CBOE VIX Future Expiring Jan 2026 (VXF26).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD:
- Aardvark Therapeutics: Clinical Momentum and 2026 Catalyst Stack Underpin Buy Rating and $26 Target
- Aardvark Therapeutics updates investor presentation on hunger therapies
- Coty downgraded, Spruce Biosciences initiated: Wall Street’s top analyst calls
- Aardvark Therapeutics initiated with an Outperform at Oppenheimer
- 3 ‘Strong Buy’ Stocks to Buy Today, 12/12/2025, According to Top Analysts